Prothena Corp Public (PRTA) EBITDA (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly EBITDA of $30.0 million for Q1 2026, up 145.8% year-over-year from $12.2 million in Q1 2025, and up 224.1% quarter-over-quarter from -$24.2 million in Q4 2025.
Prothena Corp Public (PRTA) EBITDA (2012 - 2026) Analysis & Trends
Prothena Corp Public's EBITDA history runs 15 years deep, the most recent figure standing at $30.0 million for Q1 2026.
- In Q1 2026, EBITDA rose 145.8% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at -$119.0 million (up 14.13% YoY), while the FY2025 annual figure was -$214.6 million, down 38.87% from the prior year.
- EBITDA for Q1 2026 stood at $30.0 million, up from -$24.2 million in the prior quarter.
- The five-year high for EBITDA was $58.4 million in Q2 2024, with the low at -$84.6 million in Q2 2025.
- The 5-year median for EBITDA is -$50.3 million (2022), against an average of -$38.9 million.
- The sharpest annual moves came in 2023 and 2024: EBITDA plunged 108948.61% in 2023, then jumped 187.78% in 2024.
- Prothena Corp Public's EBITDA stood at -$72000.0 in 2022, then slumped by 108948.61% to -$78.5 million in 2023, then gained by 17.34% to -$64.9 million in 2024, then soared by 62.71% to -$24.2 million in 2025, then soared by 224.1% to $30.0 million in 2026.
- Business Quant data shows PRTA's EBITDA at $30.0 million in Q1 2026, -$24.2 million in Q4 2025, and -$40.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -21.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.10 Mn |
| Mar 31, 2026 | 30.04 Mn |
| Dec 31, 2025 | -24.20 Mn |
| Sep 30, 2025 | -40.24 Mn |
| Jun 30, 2025 | -84.62 Mn |
| Mar 31, 2025 | -65.58 Mn |
| Dec 31, 2024 | -64.90 Mn |
| Sep 30, 2024 | -66.51 Mn |
| Jun 30, 2024 | 58.38 Mn |
| Mar 31, 2024 | -81.53 Mn |
| Dec 31, 2023 | -78.52 Mn |
| Sep 30, 2023 | 10.31 Mn |
| Jun 30, 2023 | -66.50 Mn |
| Mar 31, 2023 | -56.33 Mn |
| Dec 31, 2022 | -72,000.00 |
| Sep 30, 2022 | -50.33 Mn |
| Jun 30, 2022 | -43.21 Mn |
| Mar 31, 2022 | -37.94 Mn |
| Dec 31, 2021 | -33.09 Mn |
| Sep 30, 2021 | 109.23 Mn |